Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.
(1) Of the four anticholinesterases available in France for the treatment of mild to moderate Alzheimer's disease, donepezil is the reference agent. (2) Yet even donepezil is only moderately effective: only about 10% of patients show a short-lived clinical improvement. (3) Recent systematic reviews from Cochrane and NICE confirm the moderate efficacy of anticholinesterases in this setting.
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005602:France; D005702:Galantamine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D013619:Tacrine / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D005702:Galantamine; D013619:Tacrine